个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共53条记录   A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a chinese population [作者：Wang, ML; Zhang, ZZ; Zhu, HX; Fu, GB; Wang, SY; Wu, DM; Zhou, JW; Wei, QY; Zhang, ZD,期刊：Clinical Cancer Research, 页码：3633-3640 , 文章类型： Article，,卷期：2008年14-11] Purpose: MDM2 is believed to regulate the p53 level in modulating DNA repair, cell cycle control, cell growth, and apoptosis. We hypothesize that genetic variants in the MDM2 gene are associated with risk of bladder canc... Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer (vol 14, pg 2710, 2008) [作者：Portera, CC; Walshe, JM; Rosing, DR; Denduluri, N; Berman, AW; Vatas, U; Velarde, M; Chow, CK; Steinberg, SM; Nguyen, D; Yang, SX; Swain, SM,期刊：Clinical Cancer Research, 页码：3641-3641 , 文章类型： Correction，,卷期：2008年14-11] Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors [作者：Kunigal, S; Lakka, SS; Joseph, P; Estes, N; Rao, JS,期刊：Clinical Cancer Research, 页码：3617-3626 , 文章类型： Article，,卷期：2008年14-11] Purpose: Novel strategies are needed to prevent the high mortality rates of several types of cancer. These high rates stem from tumor resistance to radiation therapy, which is thought to result from the induction of matr... Gly(82)Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population [作者：Gu, HJ; Yang, L; Sun, QM; Zhou, B; Tang, NP; Cong, RH; Zeng, Y; Wang, B,期刊：Clinical Cancer Research, 页码：3627-3632 , 文章类型： Article，,卷期：2008年14-11] Purpose: It has been shown that the expression of the receptor for advanced glycation end products (RAGE) is closely associated with invasion and metastasis in gastric cancer. A Gly(82)Ser polymorphism in exon 3 of RAGE ... A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer [作者：Robertson, MJ; Kirkwood, JM; Logan, TF; Koch, KM; Kathman, S; Kirb, LC; Bell, WN; Thurmond, LM; Weisenbach, J; Dar, MM,期刊：Clinical Cancer Research, 页码：3462-3469 , 文章类型： Article，,卷期：2008年14-11] Purpose: Interleukin-18 (IL-18) is an immuncistimulatory cytokine with antitumor activity in preclinical models. A phase I study of recombinant human IL-18 (rhIL-18) was done to determine the toxicity, pharmacokinetics, ... A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies [作者：Hotte, SJ; Hirte, HW; Chen, EX; Siu, LL; Le, LH; Corey, A; Iacobucci, A; MacLean, M; Lo, L; Fox, NL; Oza, AM,期刊：Clinical Cancer Research, 页码：3450-3455 , 文章类型： Article，,卷期：2008年14-11] Purpose: Mapatumumab (TRM-1, HGS-ETR1) is a fully human agonistic monoclonal antibody that targets and activates tumor necrosis factor -related apoptosis-inducing ligand (TRAIL) receptor 1 (death receptor 4). Mapatumumab... A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies [作者：Ramalingam, SS; Egorin, MJ; Ramanathan, RK; Remick, SC; Sikorski, RP; Lagattuta, TF; Chatta, GS; Friedland, DM; Stoller, RG; Potter, DM; Ivy, SP; Belani, CP,期刊：Clinical Cancer Research, 页码：3456-3461 , 文章类型： Article，,卷期：2008年14-11] Background: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) inhibits heat shock protein 90, promotes degradation of oncoproteins, and exhibits synergy with paclitaxel in vitro. We conducted a phase I study in patients wi... Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor [作者：Steeghs, N; Gelderblom, H; t Roodt, JO; Christensen, O; Rajagopalan, P; Hovens, M; Putter, H; Rabelink, TJ; de Koning, E,期刊：Clinical Cancer Research, 页码：3470-3476 , 文章类型： Article，,卷期：2008年14-11] Purpose: Hypertension is a commonly reported side effect in antiangiogenic therapy. We investigated the hypothesis that telatinib, a small molecule angiogenesis inhibitor, impairs vascular function, induces rarefaction, ... Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor [作者：Wang, Y; Saad, M; Pakunlu, RI; Khandare, JJ; Garbuzenko, OB; Garbuzenko, OB; Vetcher, AA; Soldatenkov, VA; Pozharov, VP; Minko, T,期刊：Clinical Cancer Research, 页码：3607-3616 , 文章类型： Article，,卷期：2008年14-11] Purpose: To enhance the efficacy of cancer treatment, we propose a complex approach: simultaneous delivery to the tumor of a chemotherapeutic agent and a suppressor of hypoxia-inclucible factor alpha (HIF1A).Experimental... Oral administration of gemcitabine in patients with refractory tumors: A clinical and pharmacologic study [作者：Veltkamp, SA; Jansen, RS; Callies, S; Pluim, D; Visseren-Grul, CM; Rosing, H; Kloeker-Rhoades, S; Andre, VAM; Beijnen, JH; Slapak, CA; Schellens, JHM,期刊：Clinical Cancer Research, 页码：3477-3486 , 文章类型： Article，,卷期：2008年14-11] Purpose: To determine the toxicity, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral gemcitabine (2',2'-difluorodeoxycytidine; dFdC) in patients with cancer.Experimental Design... Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6F(ab')(2) after resection of liver metastases from colorectal cancer [作者：Ychou, M; Azria, D; Menkarios, C; Faurous, P; Quenet, F; Saint-Aubert, B; Rouanet, P; Pelegrin, M; Bascoul-Mollevi, C; Guerreau, D; Saccavini, JC; Mach, JP; Artus, JC; Pelegrin, A,期刊：Clinical Cancer Research, 页码：3487-3493 , 文章类型： Article，,卷期：2008年14-11] Purpose: To evaluate the feasibility of radioimmunotherapy (RIT) with radiolabeled anti carcinoembryonic antigen antibodies after complete resection of liver metastases (LM) from colorectal cancer.Patients and Methods: T... Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer [作者：Fiegl, H; Jones, A; Hauser-Kronberger, C; Hutarew, G; Reitsamer, R; Jones, RL; Dowsett, M; Mueller-Holzner, E; Windbichler, G; Daxenbichler, G; Goebel, G; Ensinger, C; Jacobs, I; Widschwendter, M,期刊：Clinical Cancer Research, 页码：3494-3502 , 文章类型： Article，,卷期：2008年14-11] Purpose: Chemotherapy can be an integral component of the adjuvant management strategy for women with early stage breast cancer. To date, no tool is available to predict or monitor the efficacy of these therapies. The ai... Proteasome beta subunit pharmacogenomics: Gene resequencing and functional genomics [作者：Wang, LW; Kumar, S; Fridley, BL; Kalari, KR; Moon, I; Pelleymounter, LL; Hildebrandt, MAT; Batzler, A; Eckloff, BW; Wieben, ED; Greipp, PR,期刊：Clinical Cancer Research, 页码：3503-3513 , 文章类型： Article，,卷期：2008年14-11] Purpose: The proteasome is a multisubunit cellular organelle that functions as a nonlysosomal threonine protease. Proleasomes play a critical role in the degradation of proteins, regulating a variety of cellular processe... Retinoblastoma RB94 enhances radiation treatment of head and neck squamous cell carcinoma [作者：Araki, K; Ahmad, SM; Li, GY; Bray, DA; Saito, K; Wang, D; Wirtz, U; Sreedharan, S; O'Malley, BW; Li, D,期刊：Clinical Cancer Research, 页码：3514-3519 , 文章类型： Article，,卷期：2008年14-11] Purpose: To assess whether adenovirus-mediated retinoblastoma 94 (Ad-RB94) transgene expression enhances efficacy of radiation therapy (XRT) of human head and neck squamous cell carcinoma (HNSCC).Experimental Design:The ... Direct and natural killer cell-mediated antitumor effects of low-dose Bortezomib in hepatocellular carcinoma [作者：Armeanu, S; Krusch, M; Baltz, KM; Weiss, TS; Smirnow, I; Steinle, A; Lauer, UM; Bitzer, M; Salih, HR,期刊：Clinical Cancer Research, 页码：3520-3528 , 文章类型： Article，,卷期：2008年14-11] Purpose: Hepatocellular carcinoma (HCC) displays particular resistance to conventional cytostatic agents. Alternative treatment strategies focus on novel substances exhibiting antineoplastic and/or immunomodulatory activ... Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and Bioavailability in mice by 3,4,5,6-tetrahydrouridine [作者：Beumer, JH; Eiseman, JL; Parise, RA; Joseph, E; Covey, JM; Egorin, MJ,期刊：Clinical Cancer Research, 页码：3529-3535 , 文章类型： Article，,卷期：2008年14-11] Purpose: In vivo, 2',2'-difluoro-2'-deoxycytidine (dFdC) is rapidly inactivated by gut and liver cytidine deaminase (CD) to 2',2'-difluoro-2'-deoxyuridine (dFdU). Consequently, dFdC has poor oral bioavailability and is a...